Effects of XXXX on repeated sprint ability, reactive agility time, sleep and next day performance.

@entity35 @entity1 @entity5834
AIM: This study assessed the effects of @entity5834 on repeated sprint ability (RSA), reactive agility time ( @entity35 ), sleep and next day exercise performance. METHODS: Ten moderately trained male athletes (single-blind, randomized, crossover design) ingested either @entity5834 (6 mg.kg-1 bm) or placebo 1 h before exercise. Trials were performed on the same day one week apart. Performance measures included a @entity35 test (10 trials  10.2 m, separated by 30 s), followed by 7 min of active recovery and then a RSA test (five sets of 6  20 m sprints with 25 or 60 s of recovery). The RSA was then followed by 5 min of active recovery and another @entity35 . That night, @entity1 wore a wrist sleep actigraph to bed. Next day, @entity1 repeated the @entity35 and the first set of the RSA tests. RESULTS: Significant improvements were demonstrated after @entity5834 ingestion compared to placebo for the combined total time of each set (TT; combined sets 1, 3, 5; 58.947  1.88 vs. 59.683  2.54 s, respectively; P=0.05), best sprint time (BT; next day performance; 3.176  0.10 vs. 3.230  0.12 s, respectively, P=0.01), and % decrement (combined sets 2, 4; 2.866  1.24 vs. 3.801  1.69 s, respectively; P=0.02). Moderate to strong effect sizes were found for % decrement for set 2 (Cohen's d=-0.82; 1.312  0.65 vs. 2.110  1.20 s for @entity5834 and placebo conditions, respectively) and for sets 2 and 4 combined (Cohen's d=-0.63; 2.866  1.24 vs. 3.801  1.69 for @entity5834 and placebo conditions, respectively). No significant differences were found for @entity35 or for sleep measures (P>0.05). CONCLUSION: @entity5834 improved RSA, including next day performance, but had little effect on @entity35 or sleep parameters.
